LHLily Hopkins

Lily Hopkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lily Hopkins has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of a Digital Intervention to Improve the Health Outcomes of Older Adults: Secondary Data Analysis

    by Jowinn Chew, Georgina Bartlett, Lily Hopkins, Dan Frings

    Background: The health of aging populations is among the top challenges facing global health systems. The use of mobile health (mHealth) approaches has been found to be effective in prompting changes and has been identified as a potentially valuable tool to enhance health behaviors among older adults. Objective: This study sought to explore the efficacy and acceptability of a personalized mHealth app for older adults, focusing on well-being, mental and physical health, and relationship with food. Methods: This secondary data analysis examined outcomes of real-world Holly Health users who enrolled between August 2022 and January 2023. Results: Results showed that, after the intervention, self-confidence, energy, mindfulness, health mindset, and short- and long-term mindset all improved. Furthermore, the personalized mHealth app showed a good level of acceptability among the participants. Conclusions: Engaging with this digital health intervention improved several aspects of physical and mental health, adding to existing evidence that effective and accessible tools are needed to promote healthy aging.

  • Open Access

    Experiences of women with type 2 diabetes during the pre‐pregnancy, pregnancy and postpartum periods: A systematic review of qualitative studies

    by Lily Hopkins, Noreen O'LEary, Aileen Burton, Eleanor Dyer, Angela C. Flynn, Sowmiya Gunabalasingam, Nicola Heslehurst, Artemis Kyrka, Rivka Lebrett, Claire L. Meek, et al.

    Aim: To explore the experiences of women with type 2 diabetes prior to, during and after pregnancy.Methods: Six databases were systematically searched in September 2023. Qualitative studies involving women of childbearing age living with type 2 diabetes in the pre‐pregnancy, pregnancy and postpartum periods were included. A thematic synthesis was conducted to inductively generate themes related to the experiences of women with type 2 diabetes. Descriptive themes were mapped to the Socio‐Ecological Model to generate analytical themes relating to the personal, interpersonal and organisational level impacts that underlie women's experiences. Study quality was assessed using the CASP checklist for qualitative studies.Results: Eleven papers from seven countries met the inclusion criteria. Four themes containing six subthemes were generated. At a personal level, women prioritised their desire to plan a family over ‘family planning’; however, once pregnant they were fearful for the future health of their children. At the interpersonal level, women reported that their self‐efficacy was influenced by family and socio‐cultural factors which often lacked diabetes‐specific information. At the organisational level, women described a fragmented healthcare system and felt that healthcare professionals' unfamiliarity with the reproductive health needs of women with type 2 diabetes resulted in ineffective integration into their diabetes care.Conclusion: The provision of appropriate care to women with type 2 diabetes prior to and during pregnancy is inadequate, leaving them vulnerable to increased health risks and emotional distress. Innovative ways are needed to embed reproductive healthcare into mainstream diabetes management for women with type 2 diabetes prior to and post‐pregnancy.


  • Open Access

    Medication prescribing and pregnancy-related risk factors for women with type 2 diabetes of reproductive age within primary care: a cross-sectional investigation for the PREPARED study

    by Alexandra M Famiglietti, Judith Parsons, Kia-Chong Chua, Anna Hodgkinson, Olubunmi Abiola, Anna Brackenridge, Anita Banerjee, Mark Chamley, Lily Hopkins, Katharine F Hunt, et al.

    Introduction: Women with type 2 diabetes are at risk of commencing pregnancy while using medications that are either not recommended for pregnancy or with known teratogenicity, which may contribute to adverse pregnancy outcomes. In this study, we aimed to characterize pregnancy-related risk factors and medication exposures among women with type 2 diabetes. Research design and methods: Individual health characteristics, sociodemographic information, and prescription data were extracted from the primary care records of women aged 18–45 years with type 2 diabetes in participating general practices in the UK. Prescribed medications were categorized according to suitability for pregnancy: recommended, not recommended, or not recommended but used if clinically indicated. Logistic regression was used to estimate associations between individual characteristics and medications not recommended for pregnancy. Results: Data on 725 women were extracted. Prescribed medications suggested the presence of numerous comorbidities, with diabetes medications (65%, n=471) and statins (20%, n=145) most frequently prescribed. 37% (n=268) of women took ≥3 medications, and a third (n=269) took medications not recommended for pregnancy. Among those not prescribed contraception (89%, n=646), no one met all clinically recommended pre-pregnancy criteria. In multivariable logistic regression analysis, polypharmacy (OR 3.49 95% CI 2.88 to 4.30) and age (OR 1.04 95% CI 1.00 to 1.09) were associated with use of medications not recommended for pregnancy. Conclusions: Women with type 2 diabetes have suboptimal contraceptive provision despite multiple exposures to medications not recommended for pregnancy. Regular assessment of contraceptive use, reproductive intentions, and medication review is urgently needed in primary care settings to minimize pregnancy-related risks.


  • Open Access

    Interventions to enhance pre‐pregnancy care for women with type 2 diabetes: A systematic review of the literature

    by Lily Hopkins, Angus Forbes, Janet E. Anderson, Debra Bick, Anna Brackenridge, Anita Banerjee, Mark Chamley, Kia‐Chong Chua, Angela C. Flynn, Katherine Hunt, et al.

    Aims: The aim of the study was to examine the content and impact of interventions that have been used to increase the uptake of pre‐pregnancy care for women with type 2 diabetes, and their impact on maternal and fetal outcomes.Methods: A systematic search of multiple databases was conducted in November 2021, and updated July 2022, to identify studies assessing interventions to enhance pre‐pregnancy care for women with type 2 diabetes. Over 10% of articles were screened by two reviewers at title and abstract phase, after which all selected full‐text articles were screened by two reviewers. Quality assessment was conducted using the Critical Appraisal Skills Programme checklist for cohort studies. Meta‐analysis was not possible due to study heterogeneity; therefore, narrative synthesis was conducted.Results: Four eligible cohort studies were identified. The conclusions able to be drawn by this review were limited as women with type 2 diabetes (n = 800) were in the minority in all four studies (35%–40%) and none of the interventions were exclusively tailored for them. The uptake of pre‐pregnancy care was lower in women with type 2 diabetes (8%–10%) compared with other participant groups in the studies. Pregnancy preparation indicators generally improved among all groups exposed to pre‐pregnancy care, with varying impact on pregnancy outcomes.Conclusions: This review demonstrates that previous interventions have had a limited impact on pre‐pregnancy care uptake in women with type 2 diabetes. Future studies should focus on tailored interventions for improving pre‐pregnancy care for women with type 2 diabetes, particularly those from ethnic minorities and living in poorer communities.


  • Open Access

    An integrated primary care-based programme of PRE-Pregnancy cARE to improve pregnancy outcomes in women with type 2 Diabetes (The PREPARED study): protocol for a multi-method study of implementation, system adaptation and performance

    by Rita Forde, Olubunmi Abiola, Janet Anderson, Debra Bick, Anna Brackenridge, Anita Banerjee, Mark Chamley, Kia-Chong Chua, Lily Hopkins, Katharine Hunt, et al.

    Background: The number of women of childbearing age with Type 2 diabetes(T2DM) is increasing, and they now account for > 50% of pregnancies in women with pre-existing diabetes. Diabetes pregnancies without adequate pre-pregnancy care have higher risk for poor outcomes (miscarriages, birth-defects, stillbirths) and are associated with increased complications (caesarean deliveries, macrosomic babies, neonatal intensive-care admissions). The risks and costs of these pregnancies can be reduced with pregnancy preparation (HbA1c, ≤ 6.5%, 5 mg folic acid and stopping potentially harmful medicines). However, 90% of women with T2DM, most of whom are based in primary care, are not adequately prepared for pregnancy. This study will evaluate a programme of primary care-based interventions (decision-support systems; pre-pregnancy care-pathways; pregnancy-awareness resources; professional training; and performance monitoring) to improve pregnancy preparation in women with T2DM. Methods: The study aims to optimise the programme interventions and estimate their impact on pregnancy preparation, pre-pregnancy care uptake and pregnancy outcomes. To evaluate this multimodal intervention, we will use a multi-method research design following Complex Adaptive Systems (CAS) theory, refining the interventions iteratively during the study. Thirty GP practices with ≥ 25 women with T2DM of reproductive age (18–45 years) from two South London boroughs will be exposed to the intervention. This will provide > 750 women with an estimated pregnancy incidence of 80–100 to study. The research involves: a clinical audit of processes and outcomes; a process evaluation informing intervention feasibility, implementation, and behaviour change; and a cost-consequences analysis informing future economic evaluation. Performance data will be collected via audits of GP systems, hospital antenatal clinics and pregnancy outcomes. Following CAS theory, we will use repeated measurements to monitor intervention impact on pregnancy preparation markers at 4-monthly intervals over 18-months. We will use performance and feasibility data to optimise intervention effects iteratively. The target performance for the intervention is a 30% increase in the proportion of women meeting pre-pregnancy care criteria. Discussion: The primary output will be development of an integrated programme of interventions to improve pregnancy preparation, pre-pregnancy care uptake, and reduce adverse pregnancy outcomes in women with T2DM. We will also develop an implementation plan to support the introduction of the interventions across the NHS. Trial registration: ISRCTN47576591; February 8, 2022.